{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:02:41Z","timestamp":1778594561284,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2314-B-371-002-"],"award-info":[{"award-number":["MOST 109-2314-B-371-002-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"publisher","award":["106-CCH-IRP-014, 106-CCH-IRP-015, 107-CCH-HCR-035, 108-CCH-IRP-122, 109-CCH-IRP-093, and 110-CCH-IRP-042."],"award-info":[{"award-number":["106-CCH-IRP-014, 106-CCH-IRP-015, 107-CCH-HCR-035, 108-CCH-IRP-122, 109-CCH-IRP-093, and 110-CCH-IRP-042."]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The optimal axillary lymph node (ALN) management strategy in patients diagnosed with ductal carcinoma in situ (DCIS) preoperatively remains controversial. The value of breast magnetic resonance imaging (MRI) to predict ALN metastasis pre-operative DCIS patients was evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with primary DCIS with or without pre-operative breast MRI evaluation and underwent breast surgery were recruited from single institution. The value of breast MRI for ALN evaluation, predictors of breast and ALN surgeries, upgrade from DCIS to invasive cancer, and ALN metastasis were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 682 cases with pre-operative diagnosis of DCIS were enrolled in current study. The rate of upgrade to invasive cancer were found in 34.2% of specimen, and this upgrade rate is 23% for patients who received breast conserving surgery and 40.7% for mastectomy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Large pre-operative imaging tumor size and post-operative invasive component were risk factors to ALN metastasis. Breast MRI had 53.8% sensitivity, 77.8% specificity, 14.9% positive predictive value, 95.9% negative predictive value (NPV), and 76.2% accuracy to predict ALN metastasis in pre-OP DCIS patients. In MRI node-negative breast cancer patients with MRI tumor size\u2009&lt;\u20093\u00a0cm, the NPV was 96.4%, and all these false-negative cases were N1. Pre-OP diagnosed DCIS patients with MRI tumor size\u2009&lt;\u20093\u00a0cm and node negative suitable for BCS could safely omit SLNB if whole breast radiotherapy is to be performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Breast MRI had high NPV to predict ALN metastasis in pre-OP DCIS patients, which is useful and could be provided as shared decision-making reference.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-021-02336-w","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:04:01Z","timestamp":1630501441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-2013","authenticated-orcid":false,"given":"Hung-Wen","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Lin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Tung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Pei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar-Ren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Jen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Ying","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa-Koon","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2336_CR1","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.clbc.2016.10.002","volume":"17","author":"C Heymans","year":"2017","unstructured":"Heymans C, van Bastelaar J, Visschers RGJ, Vissers YLJ. Sentinel node procedure obsolete in lumpectomy for ductal carcinoma in situ. Clin Breast Cancer. 2017;17:e87\u201393.","journal-title":"Clin Breast Cancer"},{"key":"2336_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/1754-9485.12503","volume":"61","author":"P Caswell-Smith","year":"2017","unstructured":"Caswell-Smith P, Wall M. Ductal carcinoma in situ: is core needle biopsy ever enough? J Med Imaging Radiat Oncol. 2017;61:29\u201333.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2336_CR3","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.5858\/arpa.2017-0268-OA","volume":"142","author":"MB Podoll","year":"2018","unstructured":"Podoll MB, Reisenbichler ES, Roland L, Bruner A, Mizuguchi S, Sanders MAG. Feasibility of the less is more approach in treating low-risk ductal carcinoma in situ diagnosed on core needle biopsy: ten-year review of ductal carcinoma in situ upgraded to invasion at surgery. Arch Pathol Lab Med. 2018;142:1120\u20136.","journal-title":"Arch Pathol Lab Med"},{"key":"2336_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/bjs.11377","volume":"107","author":"F Munck","year":"2020","unstructured":"Munck F, Clausen EW, Balslev E, Kroman N, Tvedskov TF, Holm-Rasmussen EV. Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. Br J Surg. 2020;107:96\u2013102.","journal-title":"Br J Surg"},{"key":"2336_CR5","doi-asserted-by":"crossref","unstructured":"Prendeville S, Ryan C, Feeley L, O\u2019Connell F, Browne TJ, O\u2019Sullivan MJ, Bennett MW. Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast. 2015;24:197\u2013200.","DOI":"10.1016\/j.breast.2015.01.004"},{"key":"2336_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/tbj.13737","volume":"26","author":"A Price","year":"2020","unstructured":"Price A, Schnabel F, Chun J, Kaplowitz E, Goodgal J, Guth A, Axelrod D, Shapiro R, Mema E, Moy L, et al. Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS). Breast J. 2020;26:931\u20136.","journal-title":"Breast J"},{"key":"2336_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10549-006-9167-2","volume":"98","author":"A Goyal","year":"2006","unstructured":"Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat. 2006;98:311\u20134.","journal-title":"Breast Cancer Res Treat"},{"key":"2336_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jamcollsurg.2004.11.012","volume":"200","author":"TW Yen","year":"2005","unstructured":"Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516\u201326.","journal-title":"J Am Coll Surg"},{"key":"2336_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/jum.14722","volume":"38","author":"YJ Shin","year":"2019","unstructured":"Shin YJ, Kim SM, Yun B, Jang M, Kim B, Lee SH. Predictors of invasive breast cancer in patients with ductal carcinoma in situ in ultrasound-guided core needle biopsy. J Ultrasound Med. 2019;38:481\u20138.","journal-title":"J Ultrasound Med"},{"key":"2336_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1245\/s10434-018-6937-0","volume":"26","author":"F Nakhlis","year":"2019","unstructured":"Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB, King TA. Evaluating the rate of upgrade to invasive breast cancer and\/or ductal carcinoma in situ following a core biopsy diagnosis of non-classic lobular carcinoma in situ. Ann Surg Oncol. 2019;26:55\u201361.","journal-title":"Ann Surg Oncol"},{"key":"2336_CR11","doi-asserted-by":"crossref","unstructured":"Lamb LR, Lehman CD, Oseni TO, Bahl M. Ductal carcinoma in situ (DCIS) at breast MRI: predictors of upgrade to invasive carcinoma. Acad Radiol. 2020;27:1994\u20139.","DOI":"10.1016\/j.acra.2019.09.025"},{"key":"2336_CR12","doi-asserted-by":"crossref","unstructured":"Lamb LR, Kim G, Oseni TO, Bahl M: Noncalcified ductal carcinoma in situ (DCIS): rate and predictors of upgrade to invasive carcinoma. Acad Radiol. 2021:28:e71\u20136.","DOI":"10.1016\/j.acra.2020.02.011"},{"key":"2336_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.crad.2014.12.019","volume":"70","author":"YT Sim","year":"2015","unstructured":"Sim YT, Litherland J, Lindsay E, Hendry P, Brauer K, Dobson H, Cordiner C, Gagliardi T, Smart L. Upgrade of ductal carcinoma in situ on core biopsies to invasive disease at final surgery: a retrospective review across the Scottish Breast Screening Programme. Clin Radiol. 2015;70:502\u20136.","journal-title":"Clin Radiol"},{"key":"2336_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1245\/s10434-013-3239-4","volume":"21","author":"L Chin-Lenn","year":"2014","unstructured":"Chin-Lenn L, Mack LA, Temple W, Cherniak W, Quinn RR, Ravani P, Lewin AM, Quan ML. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Ann Surg Oncol. 2014;21:66\u201373.","journal-title":"Ann Surg Oncol"},{"key":"2336_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/tbj.12928","volume":"24","author":"L Sorrentino","year":"2018","unstructured":"Sorrentino L, Sartani A, Bossi D, Amadori R, Nebuloni M, Truffi M, Bonzini M, Riggio E, Foschi D, Corsi F. Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified? Breast J. 2018;24:325\u201333.","journal-title":"Breast J"},{"key":"2336_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12282-018-0871-7","volume":"25","author":"Y Watanabe","year":"2018","unstructured":"Watanabe Y, Anan K, Saimura M, Koga K, Fujino M, Mine M, Tamiya S, Nishihara K, Nakano T, Mitsuyama S. Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. Breast Cancer. 2018;25:663\u201370.","journal-title":"Breast Cancer"},{"key":"2336_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/tbj.13162","volume":"25","author":"A Allen","year":"2019","unstructured":"Allen A, Cauthen A, Dale P, Jean-Louis C, Lord A, Smith B. Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. Breast J. 2019;25:103\u20136.","journal-title":"Breast J"},{"key":"2336_CR18","doi-asserted-by":"crossref","unstructured":"Verbelen H, Tjalma W, Meirte J, Gebruers N. Long-term morbidity after a negative sentinel node in breast cancer patients. Eur J Cancer Care (Engl). 2019;28:e13077.","DOI":"10.1111\/ecc.13077"},{"key":"2336_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-014-2846-5","volume":"144","author":"H Verbelen","year":"2014","unstructured":"Verbelen H, Gebruers N, Eeckhout FM, Verlinden K, Tjalma W. Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review. Breast Cancer Res Treat. 2014;144:21\u201331.","journal-title":"Breast Cancer Res Treat"},{"key":"2336_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.breast.2016.07.021","volume":"29","author":"A De Groef","year":"2016","unstructured":"De Groef A, Van Kampen M, Tieto E, Schonweger P, Christiaens MR, Neven P, Geraerts I, Gebruers N, Devoogdt N. Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: a one year follow-up study. Breast. 2016;29:102\u20138.","journal-title":"Breast"},{"key":"2336_CR21","doi-asserted-by":"crossref","unstructured":"Edge SB, Sheldon DG. Counterpoint: sentinel lymph node biopsy is not indicated for ductal carcinoma in situ. J Natl Compr Canc Netw. 2003;1:207\u201312.","DOI":"10.6004\/jnccn.2003.0019"},{"key":"2336_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326.","journal-title":"JAMA"},{"key":"2336_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-016-3783-2","volume":"156","author":"LM van Roozendaal","year":"2016","unstructured":"van Roozendaal LM, Goorts B, Klinkert M, Keymeulen K, De Vries B, Strobbe LJA, Wauters CAP, van Riet YE, Degreef E, Rutgers EJT, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res Treat. 2016;156:517\u201325.","journal-title":"Breast Cancer Res Treat"},{"key":"2336_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/jso.20578","volume":"94","author":"R Sakr","year":"2006","unstructured":"Sakr R, Barranger E, Antoine M, Prugnolle H, Darai E, Uzan S. Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol. 2006;94:426\u201330.","journal-title":"J Surg Oncol"},{"key":"2336_CR25","doi-asserted-by":"crossref","unstructured":"Bertozzi S, Cedolini C, Londero AP, Baita B, Giacomuzzi F, Capobianco D, Tortelli M, Uzzau A, Mariuzzi L, Risaliti A. Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: retrospective observational study. Medicine (Baltimore). 2019;98:e13831.","DOI":"10.1097\/MD.0000000000013831"},{"key":"2336_CR26","doi-asserted-by":"crossref","unstructured":"Hotton J, Salleron J, Rauch P, Buhler J, Pierret M, Baumard F, Leufflen L, Marchal F. Predictive factors of axillary positive sentinel lymph node biopsy in extended ductal carcinoma in situ treated by simple mastectomy at once. J Gynecol Obstet Hum Reprod. 2020;49:101641.","DOI":"10.1016\/j.jogoh.2019.101641"},{"key":"2336_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/bjs.11079","volume":"106","author":"F Magnoni","year":"2019","unstructured":"Magnoni F, Massari G, Santomauro G, Bagnardi V, Pagan E, Peruzzotti G, Galimberti V, Veronesi P, Sacchini VS. Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ. Br J Surg. 2019;106:375\u201383.","journal-title":"Br J Surg"},{"key":"2336_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.breast.2018.09.004","volume":"42","author":"EV Holm-Rasmussen","year":"2018","unstructured":"Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF. Risk factors of sentinel and non-sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide study. Breast. 2018;42:128\u201332.","journal-title":"Breast"},{"key":"2336_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-017-1197-1","volume":"15","author":"AJ Carin","year":"2017","unstructured":"Carin AJ, Moliere S, Gabriele V, Lodi M, Thiebaut N, Neuberger K, Mathelin C. Relevance of breast MRI in determining the size and focality of invasive breast cancer treated by mastectomy: a prospective study. World J Surg Oncol. 2017;15:128.","journal-title":"World J Surg Oncol"},{"key":"2336_CR30","doi-asserted-by":"crossref","unstructured":"Liu F, Wang M, Li H. Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla. World J Surg Oncol. 2018;16:239.","DOI":"10.1186\/s12957-018-1538-8"},{"key":"2336_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12957-018-1537-9","volume":"16","author":"LJ Wang","year":"2018","unstructured":"Wang LJ, Wu P, Li XX, Luo R, Wang DB, Guan WB. Magnetic resonance imaging features for differentiating breast papilloma with high-risk or malignant lesions from benign papilloma: a retrospective study on 158 patients. World J Surg Oncol. 2018;16:234.","journal-title":"World J Surg Oncol"},{"key":"2336_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12957-018-1438-y","volume":"16","author":"W Gao","year":"2018","unstructured":"Gao W, Guo N, Dong T. Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis. World J Surg Oncol. 2018;16:145.","journal-title":"World J Surg Oncol"},{"issue":"11","key":"2336_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1477-7819-11-154","volume":"12","author":"BK Killelea","year":"2013","unstructured":"Killelea BK, Grube BJ, Rishi M, Philpotts L, Tran EJ, Lannin DR. Is the use of preoperative breast MRI predictive of mastectomy? World J Surg Oncol. 2013;12(11):154.","journal-title":"World J Surg Oncol"},{"key":"2336_CR34","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ejrad.2015.12.027","volume":"85","author":"CW Lee","year":"2016","unstructured":"Lee CW, Wu HK, Lai HW, Wu WP, Chen ST, Chen DR, Chen CJ, Kuo SJ. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components. Eur J Radiol. 2016;85:780\u20139.","journal-title":"Eur J Radiol"},{"key":"2336_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12957-021-02189-3","volume":"19","author":"BB Choi","year":"2021","unstructured":"Choi BB. Dynamic contrast enhanced-MRI and diffusion-weighted image as predictors of lymphovascular invasion in node-negative invasive breast cancer. World J Surg Oncol. 2021;19:76.","journal-title":"World J Surg Oncol"},{"key":"2336_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.2016.71.0947","volume":"35","author":"GH Lyman","year":"2017","unstructured":"Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35:561\u20134.","journal-title":"J Clin Oncol"},{"key":"2336_CR37","doi-asserted-by":"crossref","unstructured":"Cody HS, Zee KJV: Point: Sentinel lymph node biopsy is indicated for patients with DCIS. J Natl Compr Canc New. 2003;1:199\u2013206.","DOI":"10.6004\/jnccn.2003.0018"},{"key":"2336_CR38","doi-asserted-by":"crossref","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, clinicalguidelines@esmo.org EGCEa: Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30:1194\u2013220.","DOI":"10.1093\/annonc\/mdz173"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02336-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:04:41Z","timestamp":1630501481000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02336-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2336"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02336-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board (IRB) of CCH, and the IRB number is 140404 and 210519.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}